Cargando…

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema

AIM: To evaluate the efficacy of intravitreal Aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at one year. METHODS: This is a prospective, non-comparative, multicenter observational study including diabetic patients whose HbA1c is < 9%, with visual acuity betw...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Thi Ha Chau, Erginay, Ali, Verdun, Stephane, Fourmaux, Eric, Le Rouic, Jean-François, Uzzan, Joel, Milazzo, Solange, Baillif, Stephanie, Kodjikian, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123959/
https://www.ncbi.nlm.nih.gov/pubmed/34007150
http://dx.doi.org/10.2147/OPTH.S304030
_version_ 1783693069336444928
author Tran, Thi Ha Chau
Erginay, Ali
Verdun, Stephane
Fourmaux, Eric
Le Rouic, Jean-François
Uzzan, Joel
Milazzo, Solange
Baillif, Stephanie
Kodjikian, Laurent
author_facet Tran, Thi Ha Chau
Erginay, Ali
Verdun, Stephane
Fourmaux, Eric
Le Rouic, Jean-François
Uzzan, Joel
Milazzo, Solange
Baillif, Stephanie
Kodjikian, Laurent
author_sort Tran, Thi Ha Chau
collection PubMed
description AIM: To evaluate the efficacy of intravitreal Aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at one year. METHODS: This is a prospective, non-comparative, multicenter observational study including diabetic patients whose HbA1c is < 9%, with visual acuity between 20/400 to 20/40 due to DME, who have undergone vitrectomy since at least 3 months before the first aflibercept injection. Treatment protocol included 5 monthly aflibercept injection followed by a ProReNata regimen during the first year. Visual acuity, OCT findings and number of IAI were assessed at 6 months and one year. RESULTS: Forty-six eyes were included. Indications for vitrectomy were epiretinal membrane (58.7%), intravitreal hemorrhage (26.1%), and vitreomacular traction (8.7%), retinal detachment (4.3%), and other cause (4.3%). Median duration of macular edema was 3 years. Median interval between vitrectomy and first visit was 9 months. Thirty eyes were non-naïve and received previously thermal laser (44.3%), intravitreal injection of triamcinolone (26.7%), of ranibizumab (70%), of dexamethasone implant (36.7%), or bevacizumab (6.7%). Data was available for 35 eyes at 1 year. Visual gain was significant, +6 letters (p <0.001) and central subfield thickness (CST) decreased significantly (−108μm, p < 0.001) at 1 year. Mean number of injections was 9.3 and mean interval injection was 5.8 weeks. CONCLUSION: These results suggest that IAI may be beneficial in vitrectomized eyes with refractory DME which require frequent injections to obtain visual and anatomical improvement. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov, registration Number NCT02874859.
format Online
Article
Text
id pubmed-8123959
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-81239592021-05-17 One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema Tran, Thi Ha Chau Erginay, Ali Verdun, Stephane Fourmaux, Eric Le Rouic, Jean-François Uzzan, Joel Milazzo, Solange Baillif, Stephanie Kodjikian, Laurent Clin Ophthalmol Original Research AIM: To evaluate the efficacy of intravitreal Aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at one year. METHODS: This is a prospective, non-comparative, multicenter observational study including diabetic patients whose HbA1c is < 9%, with visual acuity between 20/400 to 20/40 due to DME, who have undergone vitrectomy since at least 3 months before the first aflibercept injection. Treatment protocol included 5 monthly aflibercept injection followed by a ProReNata regimen during the first year. Visual acuity, OCT findings and number of IAI were assessed at 6 months and one year. RESULTS: Forty-six eyes were included. Indications for vitrectomy were epiretinal membrane (58.7%), intravitreal hemorrhage (26.1%), and vitreomacular traction (8.7%), retinal detachment (4.3%), and other cause (4.3%). Median duration of macular edema was 3 years. Median interval between vitrectomy and first visit was 9 months. Thirty eyes were non-naïve and received previously thermal laser (44.3%), intravitreal injection of triamcinolone (26.7%), of ranibizumab (70%), of dexamethasone implant (36.7%), or bevacizumab (6.7%). Data was available for 35 eyes at 1 year. Visual gain was significant, +6 letters (p <0.001) and central subfield thickness (CST) decreased significantly (−108μm, p < 0.001) at 1 year. Mean number of injections was 9.3 and mean interval injection was 5.8 weeks. CONCLUSION: These results suggest that IAI may be beneficial in vitrectomized eyes with refractory DME which require frequent injections to obtain visual and anatomical improvement. CLINICAL TRIAL REGISTRATION: http://www.clinicaltrials.gov, registration Number NCT02874859. Dove 2021-05-11 /pmc/articles/PMC8123959/ /pubmed/34007150 http://dx.doi.org/10.2147/OPTH.S304030 Text en © 2021 Tran et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Tran, Thi Ha Chau
Erginay, Ali
Verdun, Stephane
Fourmaux, Eric
Le Rouic, Jean-François
Uzzan, Joel
Milazzo, Solange
Baillif, Stephanie
Kodjikian, Laurent
One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
title One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
title_full One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
title_fullStr One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
title_full_unstemmed One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
title_short One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
title_sort one-year outcome of aflibercept intravitreal injection in vitrectomized eyes with diabetic macular edema
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123959/
https://www.ncbi.nlm.nih.gov/pubmed/34007150
http://dx.doi.org/10.2147/OPTH.S304030
work_keys_str_mv AT tranthihachau oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema
AT erginayali oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema
AT verdunstephane oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema
AT fourmauxeric oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema
AT lerouicjeanfrancois oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema
AT uzzanjoel oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema
AT milazzosolange oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema
AT baillifstephanie oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema
AT kodjikianlaurent oneyearoutcomeofafliberceptintravitrealinjectioninvitrectomizedeyeswithdiabeticmacularedema